Simple urine test could improve early detection of bladder cancer – WHO study
A new study conducted by researchers from the United Nations health agency revealed that bladder cancer mutations can be detected in urine up to 10 years before clinically diagnosing the disease. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - February 20, 2020 Category: International Medicine & Public Health Source Type: news

Simple urine test could help diagnose bladder cancer TEN YEARS before symptoms appear
International researchers used the urine test on 131 people in Iran. Almost half who developed bladder cancer could have been spotted 10 years in advance. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2020 Category: Consumer Health News Source Type: news

Seattle Genetics ’ bladder drug gets breakthrough therapy designation
Seattle Genetics ’ cancer-killing bladder drug, Padcev, has received breakthrough therapy designation from the Federal Drug Administration, the company announced Wednesday. The drug — made by the Bothell-based biotech in partnership with Japanese drug maker Astellas Pharma, which has a Seattle office — gained accelerated approval in December, three months ahead of schedule. Seattle Genetics, which is the largest biotech in the Seattle area based on employee count from 2018, recorded $916.7… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 19, 2020 Category: Pharmaceuticals Authors: Megan Campbell Source Type: news

Seattle Genetics ’ bladder drug gets breakthrough therapy designation
Seattle Genetics ’ cancer-killing bladder drug, Padcev, has received breakthrough therapy designation from the Federal Drug Administration, the company announced Wednesday. The drug — made by the Bothell-based biotech in partnership with Japanese drug maker Astellas Pharma, which has a Seattle office — gained accelerated approval in December, three months ahead of schedule. Seattle Genetics, which is the largest biotech in the Seattle area based on employee count from 2018, recorded $916.7… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 19, 2020 Category: Biotechnology Authors: Megan Campbell Source Type: news

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial TOKYO and BOTHELL, Wash., Feb. 19, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.... Biopharmaceuticals, Oncology, FDA Astellas Pharma, Seattle Genetics, Enfortumab Vedotin, Urothelial Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2020 Category: Pharmaceuticals Source Type: news

Unprecedented Response Rate in Advanced Bladder Cancer Unprecedented Response Rate in Advanced Bladder Cancer
The combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial cancer was called'very promising'by an expert not involved with an early phase trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 19, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A Failed Strategy for an Effective Bladder Cancer Drug A Failed Strategy for an Effective Bladder Cancer Drug
When the number of doses of BCG for high-grade non-muscle invasive bladder cancer was cut, outcomes were inferior in a randomized clinical trial.Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - February 17, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
The FDA   approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Bright idea in dentist's office leads to innovative smoking cessation project
Results from this study recently published online in Addiction found primary care physicians providing smokers with a free, two week starter kit of nicotine replacement therapy (NRT) increased quit attempts While sitting in the dentist's office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea. As he received his goody bag with dental hygiene products, he wondered why not conduct a study and have primary care providers do the same thing for their patients who use tobacco. The bags would contain educational material, free lozenges and tobacco cessati...
Source: Dental Technology Blog - February 12, 2020 Category: Dentistry Source Type: news

After Cancer Took His Mother, James Allison Taught Our Immune Systems How to Fight It
There once was a boy in Alice, Texas, who saw things a little differently from everybody else. Influenced by his father, a “country” doctor, he was drawn to science instead of football and conducted biology experiments in his parents’ garage. When he was 10, someone gave him a harmonica, but he never took a lesson or learned to read music, so he wandered the woods mimicking what he’d heard on the radio. A year after that, his mother died following a long struggle with lymphoma. What he still remembers decades later are her last, bedridden days when he spent hours holding her hand, and the burns sing...
Source: TIME: Health - February 6, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Research Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study examines prostate cancer treatment decisions
(Vanderbilt University Medical Center) A five-year follow-up study of more than 2,000 US men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we w...
Source: Roche Media News - January 24, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
            Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is ve...
Source: Roche Investor Update - January 24, 2020 Category: Pharmaceuticals Source Type: news

Patients With Bladder Cancer Need to Be Offered Curative Tx Patients With Bladder Cancer Need to Be Offered Curative Tx
A paradigm shift is needed in the way care is delivered to patients with muscle-invasive bladder cancer to ensure more are offered treatment with curative intent, say US experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Comparative Harms of Prostate Cancer Treatment Estimated in New Analysis Comparative Harms of Prostate Cancer Treatment Estimated in New Analysis
A new analysis provides estimates of bowel, bladder, and sexual function through five years following contemporary treatments for localized prostate cancer, which may help men clarify expectations and make more informed treatment choices, the research team says.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 16, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Study Uncovers Drug Combination for Sarcomatoid Mesothelioma
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - January 16, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemicals in Tap Water Linked to Bladder Cancer Chemicals in Tap Water Linked to Bladder Cancer
Up to 5% of bladder cancer cases in Europe could be due to exposure to disinfectants in drinking water, say researchers, who calculate that lowering levels could almost halve that number.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

5 percent of bladder cancer in Europe linked to contaminated tap water
More than 6,500 cases of bladder cancer diagnosed each year in Europe can be attributed to trihalomethane exposure through drinking water, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 15, 2020 Category: Consumer Health News Source Type: news

Tap water causes 5% of all bladder cancer cases in Europe each year
Researchers have linked drinking, showering and bathing in tap water to more than 6,500 cases (5 per cent) of the disease in 26 countries in the European Union. (Source: the Mail online | Health)
Source: the Mail online | Health - January 15, 2020 Category: Consumer Health News Source Type: news

Exposure to chemicals in drinking water associated with 5% of annual bladder cancer burden in Europe
(Barcelona Institute for Global Health (ISGlobal)) Macro study analyzes for the first time the presence and health impact of trihalomethanes in tap water in 26 European Union countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Pembrolizumab for High-Risk Bladder Cancer FDA Approves Pembrolizumab for High-Risk Bladder Cancer
Pembrolizumab is now approved for patients with bacillus Calmette-Guerin -unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Merck's Keytruda wins U.S. FDA approval for bladder cancer
The U.S. Food and Drug Administration said on Wednesday it approved Merck& Co Inc's Keytruda for a hard-to-treat form of bladder cancer, making it the first new treatment for the cancer in more than two decades. (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBC
The FDA approved pembrolizumab for the treatment of patients with BCG –unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - January 8, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Keytruda (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) January 8, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 8, 2020 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug
U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics' experimental drug to treat advanced bladder cancer, about three months ahead of schedule. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Microscopic Traces of Blood in Urine Linked to Urological Cancer Microscopic Traces of Blood in Urine Linked to Urological Cancer
Non-visible hematuria (NVH) was associated with bladder cancer (BC), upper tract urothelial carcinoma (UTUC) and kidney cancer (KC) in a systematic review and meta-analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Saccharin derivatives give cancer cells a not-so-sweet surprise
(American Chemical Society) Saccharin received a bad rap after studies in the 1970s linked consumption of large amounts of the artificial sweetener to bladder cancer in laboratory rats. Later, research revealed that these findings were not relevant to people. And in a complete turnabout, recent studies indicate that saccharin can actually kill human cancer cells. Now, researchers reporting in ACS' Journal of Medicinal Chemistry have made artificial sweetener derivatives that show improved activity against two tumor-associated enzymes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2019 Category: International Medicine & Public Health Source Type: news

ODAC Votes in Favor of Pembrolizumab for Treatment of Certain Patients with NMIBC
The anti-PD-1 therapy was recommended as a treatment for certain patients with high-risk, non-muscle invasive bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 18, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
TOKYO and BOTHELL, Wash., Dec. 18, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2019 Category: Drugs & Pharmacology Source Type: news

Prostate cancer symptoms: Problems with sleep that could signal the deadly disease
PROSTATE cancer is the most common cancer in men in the UK and it is on the rise. The symptoms are mainly associated with the bladder and there are a number of signs related to your sleeping pattern that may signal the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - December 17, 2019 Category: Consumer Health News Source Type: news

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
             Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq ® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety ...
Source: Roche Investor Update - December 13, 2019 Category: Pharmaceuticals Source Type: news

Standard pathology tests outperform molecular subtyping in bladder cancer
(Medical College of Georgia at Augusta University) While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found that sophisticated new subtyping techniques designed to do this provide no better information than long-standing pathology tests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2019 Category: Cancer & Oncology Source Type: news

Prostate cancer symptoms: This issue in cold weather could actually be sign of the disease
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - December 11, 2019 Category: Consumer Health News Source Type: news

KU Cancer Center-invented drug could eliminate need for bladder removal
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that could potentially transform the treatment of bladder cancer. Researchers at the University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed out to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm BioNovus Innovations LLC. Fosciclopirox is set to become the first… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 10, 2019 Category: Pharmaceuticals Authors: Lily Lieberman Source Type: news

KU Cancer Center-invented drug could eliminate need for bladder removal
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that could potentially transform the treatment of bladder cancer. Researchers at the University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed out to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm BioNovus Innovations LLC. Fosciclopirox is set to become the first… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2019 Category: Biotechnology Authors: Lily Lieberman Source Type: news

KU Cancer Center-invented drug targets transforming bladder cancer treatment
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that potentially could transform the treatment of bladder cancer. Researchers at The University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm Bio Novus Innovations LLC. Fosciclopirox is set to become the first KU Cancer… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 10, 2019 Category: Pharmaceuticals Authors: Lily Lieberman Source Type: news

KU Cancer Center-invented drug targets transforming bladder cancer treatment
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that potentially could transform the treatment of bladder cancer. Researchers at The University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm Bio Novus Innovations LLC. Fosciclopirox is set to become the first KU Cancer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2019 Category: Biotechnology Authors: Lily Lieberman Source Type: news

Drug Trials Snapshots: BALVERSA
BALVERSA is a drug for the treatment of a type of bladder and urinary tract cancer called urothelial carcinoma. BALVERSA may be used in patients with urothelial carcinoma: whose tumors have a certain type of abnormal (FGFR) gene and whose cancer has spread (locally advanced or metastatic urothelial (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Medical News Today: Using anthrax to fight cancer
Current treatments for bladder cancer need improvement. A new study combines a growth factor with anthrax toxin to create a quick, effective treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2019 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Permanent Hair Dyes and Chemical Straighteners May Be Linked to Breast Cancer, Study Says
Two common beauty products—permanent hair dyes and chemical straighteners—may be associated with an elevated risk for breast cancer, according to a new study published in the International Journal of Cancer. Hair dyes have been linked to other cancers before, though the research is inconclusive. Bladder and blood cancers have been examined most closely, according to the American Cancer Society, with the most consistent results pointing to a small increase in bladder cancer risk for salon employees. Meanwhile, most studies to date looking specifically at dye and breast cancer have not found a connection. The pic...
Source: TIME: Health - December 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer Source Type: news

FDA Grants Priority Review to Pembrolizumab for Non-Muscle Invasive Bladder Cancer
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the treatment of patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Bladder cancer symptoms: This sign in your pee could signal the deadly disease
BLADDER cancer, which starts in the lining of the bladder, is the 10th most common cancer in the UK and it mainly affects people aged 75 and over. Treatment and survival outcomes will greatly depend on how far the cancer has advanced so it is important to recognise the early warning signs. (Source: Daily Express - Health)
Source: Daily Express - Health - November 28, 2019 Category: Consumer Health News Source Type: news

CVD mortality much higher among cancer patients
CVD mortality highest in first year from diagnosis; and also much higher for bladder, larynx, prostate and uterine cancers Related items fromOnMedica Exercise essential for people diagnosed with cancer NHS must improve access to screening to save lives Metastatic breast cancer goes undiagnosed for too long Cancer strategies failed to improve one-year survival Cancer mortality cut by a third in young people (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 26, 2019 Category: UK Health Source Type: news

Blackstone to invest $400 million in gene therapy venture with Ferring
Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant's largest ever bet on drug development. (Source: Reuters: Health)
Source: Reuters: Health - November 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Seattle Genetics CEO wants his company to be the face of area's biotech scene
As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 20, 2019 Category: Biotechnology Source Type: news

Seattle Genetics CEO wants his company to be the face of area's biotech scene
As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 20, 2019 Category: Pharmaceuticals Source Type: news

ANTHRAX may be the key to shrinking bladder tumors by 30% in 3 minutes
A combination of anthrax and a growth factor found on the surface of bladder cancer cells allowed Purdue University researchers to target and kill tumors with unprecedented speed. (Source: the Mail online | Health)
Source: the Mail online | Health - November 13, 2019 Category: Consumer Health News Source Type: news

Anthrax may be the next tool in the fight against bladder cancer
(Purdue University) Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2019 Category: Cancer & Oncology Source Type: news